Navigation Links
Biomarkers for Alzheimer's disease can be trusted in clinical trials

Gteborg, Sweden, 15 November 2007 -- The best-established biomarkers for Alzheimers disease have a low natural variation over two years. The results speak for the inclusion of these biomarkers in clinical trials of novel drugs against Alzheimers disease.

The results are presented by researchers at the Sahlgrenska Academy at Gteborg University, Sweden, in the November 2007 issue of the Journal of Alzheimers Disease.

We show that the best-established diagnostic biomarkers for Alzheimers disease stay at basically the same level during two years in patients with early Alzheimers disease. This means that the biomarkers could be useful for detecting even minor biochemical changes induced by treatment in the clinical trials of novel drugs against Alzheimers, says Henrik Zetterberg, Associate Professor at the Sahlgrenska Academy.

Dr Zetterberg and colleagues analyzed cerebrospinal fluid from more than 80 patients with mild cognitive impairment. Some of these patients developed full-blown Alzheimers disease. The measured levels of the tau and amyloid- proteins were compared in samples drawn from the same patients two years apart.

If a novel drug candidate actually stops or slows down the neurodegenerative disease process in Alzheimer's disease, we should expect a normalized tau concentration in cerebrospinal fluid in patients on active treatment. Such a change should be readily detectable also in a small and inexpensive pilot study, given the low intra-individual variation in biomarker levels over time that was detected in our study, Dr Zetterberg says.

Alzheimer's disease is an age-related brain-damaging disorder that results in progressive cognitive impairment and death. Three decades of progress have resulted in a profound understanding of the molecular mechanisms underlying the disease. In the past 10 years, this knowledge has translated into a range of targets for therapy, the most promising of which is amyloid-.


Contact: Associate Professor Henrik Zetterberg
IOS Press

Related medicine news :

1. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
2. Study makes progress in zoning in on biomarkers for better colon cancer treatment
3. Biomarkers predict risk for invasive breast cancer years before the tumor develops
4. JDRF and Lilly partner to fund research to identify beta cell biomarkers
5. Smoking may strongly increase long-term risk of eye disease
6. Pot bellies linked to early signs of cardiovascular disease
7. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
8. Radiologists encouraged to look beyond cancer for clinically unseen diseases
9. Use of certain lipid measures not more effective in predicting coronary heart disease
10. Role seen for cannabis in helping to alleviate allergic skin disease
11. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... ... 26, 2015 , ... PRMA Plastic Surgery is updating their record books yet ... 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, ... lives and it’s an honor to have served all of these women.” , PRMA ...
(Date:11/26/2015)... Viejo, CA (PRWEB) , ... November 26, 2015 ... ... users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This ... style options. These classically-influenced trailer titles work with any font, giving users limitless ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of ... server to improve system efficiency and reliability. , The new Q-Suite 6 platform is ... the system avoids locking itself into a specific piece of software for many key ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/25/2015)... N.C. , Nov. 25, 2015 ... the planned investment of at least $15.8  Million ... Wilmington, NC . The expansion ... capacity to meet the growing demands of the ... site expansion will provide up to ...
Breaking Medicine Technology: